on MAAT PHARMA (isin : FR0012634822)
MaaT Pharma: 2025 Revenue and Clinical Progress
MaaT Pharma, a Lyon-based biotechnology company, has announced its financial results for 2025. The company generated revenue of €4.5 million, marking a 38% increase compared to 2024. This increase is mainly due to the success of the Compassionate Access Program in France.
Concurrently, MaaT Pharma has submitted a Marketing Authorization Application for MaaT013 (Xervyteg) to the European Medicines Agency. Discussions are also underway with the FDA regarding potential clinical activities in the United States. Research and development expenditures reached €29.1 million, reflecting the company's continued commitment to therapeutic innovation.
A €37.5 million financing agreement with the European Investment Bank supports these developments. Available cash at December 31, 2025, amounted to €24.9 million, enabling operations to continue until August 2026.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all MAAT PHARMA news